Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cannabist Company Holdings Inc CBSTF


Primary Symbol: N.CBST Alternate Symbol(s):  N.CCHW | N.CCHW.WT

The Cannabist Company Holdings Inc. is a cultivator, manufacturer and provider of cannabis products and related services, with licenses in 15 United States jurisdictions. The Company’s principal business activity is the production and sale of cannabis as regulated by the regulatory bodies and authorities of the jurisdictions in which it operates. The Company operates approximately 124 facilities, including 93 dispensaries and 31 cultivation and manufacturing facilities, including those under development. The Company is a multi-state provider of cannabis in the United States and delivers products and services to both the medical and adult-use markets. Its retail brand, Cannabist, creates a national dispensary network that leverages proprietary technology platforms. The Company offers products spanning flower, edibles, oils and tablets, and manufactures brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber.


NEO:CBST - Post by User

Post by AwareInvestoron Mar 19, 2021 1:35pm
597 Views
Post# 32838922

Columbia Care: Canaccord Reiterates $15 Price Target Followi

Columbia Care: Canaccord Reiterates $15 Price Target Followi
On March 16th, Columbia Care reported their fourth quarter and year end financials as well as reaffirming their 2021 guidance. For the fourth quarter, the company reported combined revenues of $81.8 million as well as adjusted EBITDA of $9.5 million. For the year end, the company stated their combined revenue to be $197.9 million and a -$0.9 million adjusted EBITDA loss.
 
The company also reiterated their 2021 guidance of revenues between $500 and $530 million with adjusted EBITDA to be in the area of $100 million.
 
Columbia Care currently has 11 analysts covering the company with a weighted 12-month price target of C$13.42. This is up from the average last month, which was C$12.00. Four analysts have strong buys while another six have buy ratings, and one analyst has a hold rating on the name. The street high comes from Cantor Fitzgerald with a C$16.50 price target, and the lowest target comes from Paradigm Capital with an C$11.50 price target.

https://thedeepdive.ca/columbia-care-canaccord-reiterates-15-price-target-following-q4-results/
<< Previous
Bullboard Posts
Next >>